publication date: Aug. 3, 2010In this issue: Taking Profit Out Of ESAs, Insurer Sending Controversial Drugs Directly To Patients. ODAC Votes Against Cell Therapeutics Agent; Requires ChemGenex To Develop Diagnostic. Report Urges Changes To Cut Activation Times For NCI Phase III Trials. AACR Elects Officers. Download PDF
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.